Nomogram for visual acuity outcome after iodine-125 plaque radiotherapy and prophylactic intravitreal bevacizumab for uveal melanoma in 1131 patients

COMMENTED

Ocular Oncology

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals

★ 3 Recommended and commented by Dr habil. Gábor Márk Somfai, PhD, Faculty Member

doi: 10.1001/jamaophthalmol.2019.5132.

Ocular Oncology

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Clin Exp Ophthalmol.

Yang X, Dalvin LA, Mazloumi M, Chang M, Shields JA, Mashayekhi A, Shields CL

doi: 10.1111/ceo.13758.

Ocular Oncology

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

JAMA Ophthalmol.

Shields CL, Sioufi K, Srinivasan A, DiNicola M, Masoomian B, Barna LE, Bekerman VP, Say EAT, Mashayekhi A, Emrich J, Komarnicky L, Shields JA

doi: 10.1001/jamaophthalmol.

Ocular Oncology

Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

BMC Ophthalmol

Fang R, Wang H, Li Y, Liu YM, Wei WB

doi: 10.1186/s12886-021-01898-3

Macular Diseases

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Eye (Lond).

Chatziralli I, Regan SO, Mohamed R, Talks J, Sivaprasad S; UK Aflibercept Users Group.

doi: 10.1038/s41433-018-0114-3.

Ocular Oncology

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Ophthalmology.

Vichitvejpaisal P, Dalvin LA, Mazloumi M, Ewens KG, Ganguly A, Shields CL

doi: 10.1016/j.ophtha.2019.04.027.

Macular Diseases

Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register

Acta Ophthalmol.

Lövestam Adrian M, Vassilev ZP, Westborg I

doi: 10.1111/aos.13864.

Ocular Oncology

Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates

Acta Ophthalmol

van Beek JGM, van Rij CM, Baart SJ, Yavuzyigitoglu S, Bergmann MJ, Paridaens D, Naus NC, Kiliç E

doi: 10.1111/aos.15029

Uveitis

Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis

JAMA.

Writing Committee for the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study Research Group, Kempen JH, Altaweel MM, Holbrook JT, Sugar EA, Thorne JE, Jabs DA

doi: 10.1001/

Related content

Visual Outcome at 4 Years Following Plaque Radiotherapy and Prophylactic Intravitreal Bevacizumab (Every 4 Months for 2 Years) for Uveal Melanoma: Comparison With Nonrandomized Historical Control Individuals

Impact of uveal melanoma thickness on post-plaque radiotherapy outcomes in the prophylactic anti-vascular endothelial growth factor era in 1131 patients

Visual Outcome and Millimeter Incremental Risk of Metastasis in 1780 Patients With Small Choroidal Melanoma Managed by Plaque Radiotherapy

Regression patterns of uveal melanoma after iodine-125 plaque brachytherapy

Intravitreal aflibercept for neovascular age-related macular degeneration in patients aged 90 years or older: 2-year visual acuity outcomes

Genetic Analysis of Uveal Melanoma in 658 Patients Using the Cancer Genome Atlas Classification of Uveal Melanoma as A, B, C, and D

Baseline visual acuity as a prognostic factor for visual outcomes in patients treated with aflibercept for wet age-related macular degeneration: data from the INSIGHT study using the Swedish Macula Register

Fractionated stereotactic radiotherapy for uveal melanoma: Long-term outcome and control rates

Association Between Long-Lasting Intravitreous Fluocinolone Acetonide Implant vs Systemic Anti-inflammatory Therapy and Visual Acuity at 7 Years Among Patients With Intermediate, Posterior, or Panuveitis